Tango Therapeutics Announces Major Stock Offering

The latest announcement is out from Tango Therapeutics ( (TNGX) ).

On October 23, 2025, Tango Therapeutics announced a registered direct offering of 21,023,337 shares of common stock and pre-funded warrants to purchase an additional 3,226,458 shares, expected to raise approximately $197 million. The proceeds will be used to advance the company’s pipeline and support general corporate purposes, with the offering anticipated to close on October 24, 2025. Additionally, Tango entered into a private placement agreement with an accredited investor for 1,732,101 shares, expected to generate $15 million. These financial moves are intended to fund operations and capital expenditures into 2028, strengthening Tango’s position in the biotechnology industry.

The most recent analyst rating on (TNGX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.

Spark’s Take on TNGX Stock

According to Spark, TipRanks’ AI Analyst, TNGX is a Neutral.

The overall stock score for Tango Therapeutics is primarily impacted by its financial performance, which is currently weak due to declining revenues and persistent losses. Technical analysis provides a more positive outlook with bullish indicators, but the negative valuation metrics, including a negative P/E ratio, weigh down the overall score. The absence of earnings call data and corporate events means these factors do not influence the score.

To see Spark’s full report on TNGX stock, click here.

More about Tango Therapeutics

Tango Therapeutics is a biotechnology company focused on developing targeted cancer therapies. The company specializes in precision oncology, leveraging its expertise to create treatments that target specific genetic alterations in cancer cells.

Average Trading Volume: 2,552,286

Technical Sentiment Signal: Buy

Current Market Cap: $963.5M

See more data about TNGX stock on TipRanks’ Stock Analysis page.